Showing recent highlights
What's New
PubMed · September 1, 2026
Researchers found that people with rheumatoid arthritis — a condition where the immune system attacks the joints, causing pain and swelling — use physical and occupational therapy at very different rates depending on where they live, with people in European countries generally receiving these services more often than those in North America. The review also found that physical therapy was used far more than occupational therapy, which helps people manage daily tasks affected by their condition. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a rare lung complication of lupus called shrinking lung syndrome — where the lungs gradually become smaller and breathing becomes harder — responded well to treatment in most patients, with 75 to 95 percent experiencing symptom relief. However, only about 1 in 5 patients fully regained normal lung function, meaning most people were left with some lasting breathing difficulty. For patients who didn't respond to standard steroid treatment, a medication called rituximab (a drug that targets certain immune cells) showed promise as a next step. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that adding a medication called voclosporin to the usual treatment for lupus nephritis — a type of kidney damage caused by lupus — helped reduce protein in the urine much more effectively than standard treatment alone, which is a sign that the kidneys are being better protected. However, the study also found that people taking voclosporin experienced more side effects and serious medical events, raising real questions about how safely it can be used. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a drug called litifilimab helped reduce skin symptoms in people with a form of lupus that mainly affects the skin — a condition that currently has no approved targeted treatments. In the study, people taking litifilimab were more likely to see noticeable skin improvement compared to those taking a placebo (an inactive treatment), with some showing results as early as four weeks in. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a computerized decision-support tool designed to help people with lupus understand their treatment options was well-received — around 78% to 92% of nearly 1,900 patients rated the information as good to excellent, and 90% found it helpful for thinking through treatment choices. People especially appreciated the content and the clear layout, though some wanted even more detail about their medication options. Tools like this could make it easier for patients to feel informed and involved in conversations with their doctor about managing lupus. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 18, 2026
Researchers found that in studies testing treatments for the skin symptoms of lupus — a disease where the immune system mistakenly attacks the body — patients who received a placebo (a dummy treatment with no active medicine) still showed meaningful improvement in their skin. This 'placebo response' matters because when people in the comparison group get better on their own, it makes it harder for researchers to tell whether a real treatment is actually working. Understanding how often and why this happens could help scientists design better studies and eventually find treatments that are formally approved for lupus skin disease, since none currently exist specifically for this condition. This is early research and hasn't yet changed treatment guidelines.
What's New
NEJM · August 15, 2026
Researchers found that certain medications can actually trigger a specific form of lupus that affects the skin, called subacute cutaneous lupus erythematosus — meaning the drug itself may be causing or worsening the condition rather than the underlying disease alone. This matters for people with lupus because it suggests that reviewing the medications someone is already taking could be an important piece of figuring out why their symptoms are flaring or appearing in the first place. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 14, 2026
Researchers found that a new type of immune cell therapy — made from umbilical cord blood and engineered to target and wipe out certain immune cells that drive lupus — helped five people with hard-to-treat lupus go into low disease activity or even full remission, with very few side effects. Unlike similar treatments that can cause serious reactions, this approach was remarkably well tolerated, with no dangerous immune overreactions or nerve-related complications. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · August 4, 2026
According to the Sociedad Española de Reumatología (a major Spanish rheumatology organization) guidelines, doctors treating lupus now have three approved biological therapies — belimumab, anifrolumab, and obinutuzumab — to choose from, and these treatments are being used earlier in the course of the disease than before. Each option works somewhat differently and suits different aspects of lupus, so the choice depends on a person's specific situation, including how fast they need relief and their individual safety considerations. For people with lupus nephritis (a form of lupus that affects the kidneys), these newer therapies are now considered a first-line option because they have shown better outcomes than standard treatment alone.
Ask your doctor: Ask the doctor whether the patient might be a good candidate for belimumab, anifrolumab, or obinutuzumab, since those are newer biological treatments for lupus that have shown strong evidence of working.
What's New
PubMed · August 1, 2026
A study found that people with lupus who did high-intensity interval training — short bursts of intense exercise — three times a week for 12 weeks meaningfully improved their aerobic fitness (how well the body uses oxygen during activity) compared to those who didn't exercise. However, the training didn't significantly reduce fatigue, and researchers noticed that people with higher levels of a lupus-related immune signal called type 1 interferons seemed to benefit less from the exercise, though this finding was not conclusive. This could matter for people with lupus because it suggests structured exercise may support physical fitness, but the relationship between lupus disease activity and exercise response may be complex. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that two biologic medications used for lupus — belimumab and anifrolumab — both worked better than a placebo at reducing lupus symptoms, but anifrolumab showed a stronger overall response by one key measure. However, people taking anifrolumab were significantly more likely to develop a herpes zoster infection (commonly known as shingles) compared to those taking belimumab. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that a higher starting dose of anifrolumab — a treatment that works by calming an overactive immune signal linked to lupus — may work better for people with lupus nephritis, which is a form of kidney damage caused by lupus. The higher dose appeared to reduce protein in the urine more quickly (having too much protein in the urine is a sign that the kidneys are under stress), and patients who responded well were less likely to stop treatment early. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that people with lupus nephritis — a type of kidney inflammation caused by lupus — who took belimumab (a medication that calms the part of the immune system that attacks the kidneys) alongside a common treatment called mycophenolate mofetil had better kidney outcomes than those who took mycophenolate mofetil alone. The study looked specifically at patients with more active, inflammatory forms of lupus kidney disease over about two years, tracking how well the kidneys were functioning and how much protein was spilling into the urine — a key sign of kidney stress. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether adding belimumab to the patient's mycophenolate mofetil treatment might help protect the kidneys better than mycophenolate mofetil alone if the patient has lupus affecting the kidneys.
What's New
PubMed · August 1, 2026
Researchers found that hydroxychloroquine — a medication commonly used to manage lupus during pregnancy — did not appear to increase the risk of serious birth defects across 14 studies involving nearly 5,000 pregnancies. The research also noted that the medication was linked to better outcomes for babies and fewer lupus flares for the mother during pregnancy, which could be reassuring for people with lupus who are pregnant or planning to become pregnant. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that tacrolimus — a medication used to suppress the immune system — may help protect the kidneys in people with lupus nephritis, which is a form of lupus that attacks the kidneys. Specifically, the study found that tacrolimus reduced the amount of protein leaking into the urine (a sign of kidney stress) better than some other treatments, and it appeared to cause slightly fewer side effects. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that women with lupus — an immune system condition that can affect many parts of the body — who watched a short educational video about lupus and pregnancy became much better informed about how lupus can affect pregnancy outcomes, compared to women who only received standard counseling. The video also made more women interested in longer-lasting birth control options right after watching it, though that difference faded by the one-month follow-up. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that a short program of talk therapy — specifically a type called cognitive behavioral therapy, which helps people recognize and shift unhelpful thought patterns — delivered over six remote sessions helped young people with lupus feel less depressed and less fatigued compared to those who received only standard medical care. Lupus is an autoimmune condition where the body's immune system mistakenly attacks healthy tissue, and it often comes with emotional and physical challenges beyond the physical symptoms. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that anifrolumab, a medication already approved for lupus, may help reduce signs of kidney inflammation much faster than standard treatment alone in people with lupus nephritis — a serious form of lupus that attacks the kidneys. They tracked specific proteins in urine samples and found that certain inflammation markers dropped significantly within 12 weeks in people taking anifrolumab, compared to those who weren't. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 11, 2026
Researchers found that a newer lupus medication called telitacicept may work better than another lupus drug called belimumab at calming lupus activity and protecting the kidneys — two things that matter a lot for people living with lupus, since kidney damage is one of the most serious complications of the disease. In the studies reviewed, people taking telitacicept were roughly twice as likely to reach a low disease activity state and to show full kidney recovery at six months compared to those taking belimumab. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether telitacicept might work better than belimumab for treating the patient's lupus symptoms.
What's New
PubMed · July 6, 2026
Researchers found that a drug called anifrolumab helped people with lupus — a condition where the immune system mistakenly attacks the body — in two important ways: it reduced lupus disease activity and allowed many patients to lower their doses of steroids, which can cause serious side effects when taken long-term. In real-world use outside of clinical trials, about 3 in 4 patients reached a state of low disease activity within 6 to 12 months, which means their lupus symptoms were much better controlled. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether anifrolumab might help the patient's lupus symptoms and whether it could mean needing less of the steroid medications the patient is currently taking.
What's New
PubMed · July 3, 2026
Researchers found that belimumab (a medication used to treat lupus, sold as Benlysta) helped more people with lupus reach a state of low disease activity or near-remission compared to a placebo — meaning their lupus became much calmer and easier to manage. About 32% of people taking belimumab reached a low disease activity state by the end of the study, compared to 21% taking the placebo, and those with more severe lupus at the start seemed to benefit the most. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether belimumab might help the patient achieve remission or low disease activity in lupus, especially if the patient is trying to reduce steroid use.
What's New
PubMed · July 1, 2026
Researchers found that a new oral medication called enpatoran helped reduce skin symptoms in people with lupus — a disease where the immune system mistakenly attacks the body — compared to those who took a placebo (a dummy pill with no active ingredient). The drug works by blocking certain immune signals, called TLR7 and TLR8, that are thought to drive lupus flares, and it was tested across hundreds of patients in multiple countries over 24 weeks. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that in people with lupus-related kidney disease (where the immune system attacks the kidneys), a medication called belimumab helped reduce certain immune system markers — such as specific antibodies that can harm the body — while improving other protective levels in the blood. The study also identified some early biological signals that may help predict which patients are more likely to respond well to belimumab, which could one day help doctors personalize treatment decisions. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that a specific antibody test — called anti-DFS70 — was once thought to be useful for ruling out lupus, since healthy people seemed to have it more often than people with lupus. However, after combining results from 16 studies covering more than 6,000 people, researchers found that people with lupus and healthy people had the antibody at surprisingly similar rates, meaning the test isn't reliable enough on its own to tell doctors whether someone does or doesn't have lupus. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
A study found that in people with lupus who had kidney involvement (called lupus nephritis) and were in remission — meaning their disease was calm and not causing obvious symptoms — a temporary increase in immune-suppressing medication helped prevent flare-ups from coming back. Researchers noticed that some patients showed signs of disease activity in their blood tests even when they felt fine, and boosting their treatment early appeared to stop kidney and other flares from happening over the following two years. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · July 1, 2026
According to the American College of Rheumatology (ACR) guidelines, people with lupus (a condition where the immune system mistakenly attacks the body) should be treated consistently with hydroxychloroquine, a commonly used lupus medication, while keeping steroid use as short as possible and starting stronger immune-calming therapies early on. The goal is to get lupus under control quickly — reaching remission (meaning the disease is quiet or very low activity) — to reduce serious long-term harm and death related to the condition. These guidelines apply to both children and adults with lupus, and are meant to help patients and their doctors make well-informed decisions together about the best path forward.
Ask your doctor: Ask the doctor whether the patient's current lupus treatment plan follows the 2025 American College of Rheumatology guidelines and if there are any recommended changes based on how the patient is doing.
What's New
PubMed · July 1, 2026
Researchers found that a drug called deucravacitinib, taken as a pill, appears to calm down certain overactive immune signals in people with lupus — particularly signals driven by a protein called interferon, which is known to fuel inflammation in the disease. The drug seemed to shift immune cell activity in the blood closer to patterns seen in healthy people, which suggests it may be working in ways that could help ease lupus symptoms. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that a specialized immune cell treatment called CAR-T therapy — where a patient's own immune cells are reprogrammed in a lab to target problem cells — showed promising early results for people with lupus, including children. Most patients saw their lupus become less active, and many were able to stay that way without taking immune-suppressing medications, which is a big deal since those drugs can have serious side effects. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 30, 2026
Researchers found that dapagliflozin — a diabetes medication like Jardiance or Invokana — significantly reduced protein leaking into the urine in people with inactive lupus kidney disease, with a 36% reduction compared to just 3.5% in those on standard care alone. This matters because high levels of protein in the urine are a sign that the kidneys are under stress, and reducing it may help protect kidney function over time. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 30, 2026
Researchers found that Asian patients with lupus nephritis — a form of lupus that attacks the kidneys — who took a medication called voclosporin were more likely to see their kidney protein levels return to a healthy range compared to those who didn't take it (90% vs. 57%), and they got there much faster (about 6 months vs. nearly 27 months). The medication was generally well-tolerated, though some patients did experience higher rates of reduced kidney function and high blood pressure compared to the control group. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.